Form 4: NBIX Director Sells Shares After Option Exercise

Neurocrine Biosciences Director William H. Rastetter exercised options and sold 18,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• William H. Rastetter, a Director of Neurocrine Biosciences Inc. (NBIX), executed a transaction on November 5, 2025.
• The transaction involved the exercise of 18,000 non-qualified stock options at an exercise price of $47.89 per share.
• Concurrently, 18,000 shares of common stock were sold at a weighted average price of $151.8161 per share, ranging from $150.00 to $153.01.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Rastetter on August 6, 2025.
• Following these transactions, Mr. Rastetter's direct beneficial ownership of common stock is 0 shares, while 40,360 shares are held indirectly by the Rastetter Family Trust, over which he has voting and investment power.
• The non-qualified stock options were granted on May 20, 2016, vested in 12 equal monthly installments starting June 20, 2016, and were due to expire on May 20, 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the planned nature of the transaction (10b5-1 plan) and the significant profit realized by the insider, which reflects positively on the company's stock performance over time. The sale itself is neutral given it was pre-scheduled.

Positives

• The Director realized a significant profit by exercising options at $47.89 and selling shares at a weighted average of $151.8161.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent disposition rather than an immediate reaction to new information.

Negatives

• The sale of shares by a Director, even if pre-planned, could be perceived by some investors as a reduction in insider confidence, although the planned nature mitigates this concern.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if planned, might lead to minor concerns about insider sentiment, but the pre-scheduled nature under a 10b5-1 plan generally mitigates negative interpretations.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (option exercise and sale) under a Rule 10b5-1 plan. Such transactions are generally not considered indicative of new material information or a change in the company's fundamental outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Neurocrine Biosciences, NBIX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Director Transaction, Biotechnology